ULGX (Urologix) Cyclically Adjusted FCF per Share: $0.00 (As of Mar. 2015)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Urologix Cyclically Adjusted FCF per Share?

Urologix ULGX Cyclically Adjusted FCF per Share is $0.00 as of Mar. 2015.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Urologix's adjusted free cash flow per share for the three months ended in Mar. 2015 was $-0.002. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Mar. 2015.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-09-10), Urologix's current stock price is $0.0001. Urologix's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2015 was $0.00. Urologix's Cyclically Adjusted Price-to-FCF of today is .


Urologix  (OTCPK:ULGX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Urologix Cyclically Adjusted FCF per Share Related Terms


Urologix Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Urologix's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Urologix Cyclically Adjusted FCF per Share Chart

Urologix Annual Data
Trend Jun05 Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Urologix Quarterly Data
Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ULGX vs MFST, GTHP, ESMC: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, Urologix's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Urologix Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Urologix's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Urologix's Cyclically Adjusted Price-to-FCF falls into.



Urologix Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Urologix's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2015 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2015 (Change)*Current CPI (Mar. 2015)
=-0.002/236.1190*236.1190
=-0.002

Current CPI (Mar. 2015) = 236.1190.

Urologix Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200506 0.040 194.500 0.049
200509 -0.035 198.800 -0.042
200512 0.033 196.800 0.040
200603 0.001 199.800 0.001
200606 0.017 202.900 0.020
200609 -0.017 202.900 -0.020
200612 0.085 201.800 0.099
200703 -0.016 205.352 -0.018
200706 0.030 208.352 0.034
200709 -0.019 208.490 -0.022
200712 0.010 210.036 0.011
200803 -0.029 213.528 -0.032
200806 -0.050 218.815 -0.054
200809 -0.128 218.783 -0.138
200812 -0.047 210.228 -0.053
200903 -0.062 212.709 -0.069
200906 -0.042 215.693 -0.046
200909 -0.073 215.969 -0.080
200912 0.001 215.949 0.001
201003 -0.017 217.631 -0.018
201006 -0.004 217.965 -0.004
201009 -0.069 218.439 -0.075
201012 -0.028 219.179 -0.030
201103 -0.034 223.467 -0.036
201106 -0.050 225.722 -0.052
201109 -0.074 226.889 -0.077
201112 0.001 225.672 0.001
201203 0.018 229.392 0.019
201206 0.002 229.478 0.002
201209 -0.021 231.407 -0.021
201212 -0.020 229.601 -0.021
201303 0.010 232.773 0.010
201306 -0.069 233.504 -0.070
201309 -0.035 234.149 -0.035
201312 -0.013 233.049 -0.013
201403 -0.021 236.293 -0.021
201406 -0.005 238.343 -0.005
201409 -0.008 238.031 -0.008
201412 0.001 234.812 0.001
201503 -0.002 236.119 -0.002

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $0.00 mean?
Urologix (ULGX) has a Cyclically Adjusted FCF per Share of $0.00 as of Mar. 2015. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Urologix and its competitors.
Is Urologix's Cyclically Adjusted FCF per Share too high?
Urologix's current Cyclically Adjusted FCF per Share is $0.00.
How does Urologix's Cyclically Adjusted FCF per Share compare to MFST and GTHP?
Urologix's Cyclically Adjusted FCF per Share of $0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Urologix and its competitors. Urologix's current Cyclically Adjusted FCF per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Urologix stock overvalued right now?
Urologix (ULGX) has a current Cyclically Adjusted FCF per Share of $0.00. The current Cyclically Adjusted FCF per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Urologix (ULGX), the current Cyclically Adjusted FCF per Share is $0.00 as of Mar. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Urologix Business Description

Address 14405 21st Avenue North, Suite 110, Minneapolis, MN, USA, 55447
Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.